Hi! This is where health and tech intersect!

In today’s healthtech in a nutshell:

Scaling Sustainability: Deep Blue Biotech’s Journey Toward Carbon-Negative Manufacturing

The summary:

Deep Blue Biotech, a U.K.-based biotech startup founded in May 2023, is revolutionizing chemical production with a photosynthesis-based biomanufacturing process that leverages genetically engineered cyanobacteria (blue-green algae). The startup claims its approach delivers superior product functionality compared to previous green chemical attempts, overcoming consumer and industry resistance to sustainable alternatives. Recently, it secured $800,000 in pre-seed funding to scale production, file patents, and develop additional products.

Key points:

• Innovative and Sustainable Biomanufacturing: Deep Blue Biotech utilizes genetically engineered cyanobacteria in a photosynthesis-driven process to produce chemicals like hyaluronic acid. Unlike precision fermentation, which relies on expensive feedstocks like sugar, this method only requires light, water, and CO₂, making it both cost-effective and environmentally positive (net carbon-negative).

• Strategic Market Entry with High-Impact Products: The startup’s first focus is on the beauty and cosmetics industry, starting with low molecular weight hyaluronic acid, which offers high skin penetration. This choice reflects a strategic approach to use the beauty sector's strong consumer engagement to normalize sustainable products. Future expansions are planned into textiles (e.g., green fabric dyes) and other high-margin sectors.

• Scalable Technology with a Competitive Edge: By employing a high-productivity strain of cyanobacteria that grows three times faster and produces seven times more than traditional strains, Deep Blue Biotech addresses previous commercialization limitations in biomanufacturing. Its modular photobioreactors, which use transparent tubes to allow light penetration, enable a simple and scalable production system that can expand capacity efficiently. This positions the startup as a frontrunner in green chemical production, alongside notable players like Microphyt and Bondi Bio.

Why this matters:

This technology directly addresses the dual challenges of climate change and unsustainable industrial practices. By producing chemicals in a carbon-negative, resource-efficient manner, the startup represents a critical step toward decarbonizing industries heavily reliant on fossil-fuel-derived inputs. Its focus on high-value, consumer-facing markets like cosmetics demonstrates a pragmatic approach to driving early adoption and changing perceptions of sustainable products. If successful, its scalable technology could catalyze widespread industrial shifts, helping to align production practices with global climate and sustainability goals.

Roon Secures $15M to Bring Trustworthy Medical Advice to Patients

The summary:

Backed by its recent $15M raise, Roon is a healthtech startup founded by Vikram Bhaskaran, Rohan Ramakrishna, and Arun Ranganathan to address the difficulty of finding reliable health information online. Motivated by personal experiences with illness, the founders built a video-based platform where doctors share clear, clinically accurate answers to common medical questions. With over 16,000 videos covering diseases like ALS, glioblastoma, and PCOS, Roon aims to become the go-to resource for trusted medical content.

Key points:

• A Scalable, Doctor-Led Content Platform: Roon seeks to replace unreliable online health searches with a video Q&A platform where doctors from leading institutions provide personalized answers to common medical concerns. Unlike traditional medical platforms, Roon’s content is created by experts and is easily accessible to patients and caregivers outside of clinical settings. The platform currently focuses on critical health topics like ALS, dementia, and fertility and plans to expand into broader areas, including pediatrics, oncology, and metabolic health.

• A New Model for Empowering Patients: By providing accessible and trustworthy medical advice, Roon empowers patients to better understand their conditions and engage more effectively with their doctors. The platform can serve as an educational tool, supplementing pre- and post-appointment care, and helps patients make informed decisions. This approach addresses the anxiety and information overload often associated with medical research online, providing clarity and reassurance.

• High Investor Confidence Despite No Revenue Model: Roon has raised $15 million at a $68 million valuation from top-tier investors like Forerunner Ventures, FirstMark, Sequoia Capital, and TMV. While the startup has yet to develop a revenue model, investors see potential for monetization through ads, hospital subscriptions, or even a doctor directory. The focus for now is on scaling the platform and building trust with users, a strategy that resonates with consumer-focused investors who prioritize long-term value creation.

Why this matters:

The growing reliance on the internet for medical information has created a pressing need for reliable, accessible, and clinically accurate resources. Roon addresses this gap by providing a platform where patients can hear directly from doctors, fostering trust and clarity in an area often plagued by misinformation. Its emphasis on video content adds a personal and engaging dimension that text-based platforms like WebMD and Healthline lack. This has the potential to transform patient-doctor interactions, making appointments more productive and less stressful. With strong investor backing and a scalable approach, Roon could set a new standard for health communication in the digital age.

Medtronic’s GI Genius Scales Across the US with New VA Contract

The summary:

Medtronic has secured a three-year contract with the Department of Veterans Affairs (VA) to install nearly 100 additional GI Genius AI-powered endoscopy units across U.S. VA medical centers, expanding its existing partnership. GI Genius uses real-time AI to enhance polyp detection during colonoscopies, improving early identification of adenomas and potentially reducing colorectal cancer rates. This deal brings the total number of units installed at VA facilities to over 360, reflecting the VA’s commitment to advancing AI-driven tools for better patient outcomes in colorectal cancer screening.

Key points:

• Expanded Partnership with the VA: Medtronic’s new contract builds on a 2022 agreement to install 115 GI Genius units at VA facilities. With this expansion, more than 360 units will now be in place across 140 VA centers, including Puerto Rico, reinforcing the VA's dedication to integrating advanced AI solutions into its colorectal cancer screening programs.

• Clinical Validation of AI in Colonoscopy: GI Genius has demonstrated significant clinical impact in detecting adenomas, with Medtronic’s randomized trial showing a 54.8% detection rate compared to 40.4% without the technology. Early and accurate detection of adenomas is crucial to reducing colorectal cancer incidence and mortality, as missed adenomas can develop into cancer.

• Broader AI Integration in Medtronic’s Portfolio: This deployment aligns with Medtronic’s broader AI strategy, which includes leveraging Tempus’ Next platform to identify patients for other medical interventions. By embedding AI into its medical devices, Medtronic is advancing precision medicine and improving outcomes across various healthcare domains.

Why this matters:

The adoption of AI-powered tools like GI Genius marks a significant step in transforming how healthcare systems address cancer detection and prevention. For the VA, which performs around 250,000 colonoscopies annually and diagnoses 4,000 cases of colon cancer each year, integrating advanced AI technology ensures more reliable, accurate screenings. Early detection of adenomas is critical to preventing colorectal cancer, which remains a leading cause of cancer-related deaths. This deployment not only benefits veterans but also underscores how AI can enhance healthcare delivery on a large scale.

A healthtech event on the horizon:

GIANT Health Conference 2024: Shaping the Future of Healthcare

On December 9th and 10th 2024, the Business Design Centre in London will host the GIANT Health Event, the UK’s premier innovation festival for the National Health Service (NHS). This gathering, alike to other global healthtech conferences, is dedicated to revolutionizing healthcare by bringing together leading clinicians, policymakers, investors, and health-tech innovators to spark collaboration and drive meaningful change. Featuring over 100 world-class speakers, hands-on exhibits, and unmatched networking opportunities, GIANT Health offers a front-row seat to cutting-edge advancements transforming the industry. Froma diversity of breakthrough AI tools to integrated care solutions, this event is a hotspot for showcasing real-world innovations tackling critical healthcare challenges.

Some Agenda Highlights:

1. "The Future of Healthcare is Female"

   Date/Time: December 10, 2024, 10:00 - 10:45

   Summary: This panel addresses the historical underrepresentation of women in research and product development. It discusses the responsibilities of startups, investors, corporates, and healthcare leaders in championing better healthcare products and services for women to create health equity.

   
   Key Speakers:

   Kate Lancaster (CEO, Royal College of Obstetrics and Gynaecology)

   Paula Bellostas Mugerza (Senior Partner and Global Healthcare & Life Sciences Practice Leader, Kearney)

   Alexandra Oti (Co-Founder, Unravel Health)

   Erin Beveridge (Principal Clinical Researcher, Canon Medical Research Europe Ltd.)

   Miriam Kenrick (Co-Founder, Women In Pharma and #BeyondBikiniMedicine)
   

2. "From Med to MedTech: Adapting the Art of Caregiving in the Digital Revolution"

   Date/Time: December 10, 2024, 10:45 - 11:30

   Summary: This panel explores how technology can empower women to take an active role in improving their health outcomes through knowledge and access to care. It focuses on improving early education about menstrual health, harnessing AI for diagnosing conditions like endometriosis, and evolving virtual consultations to make specialist care more accessible.

   
   Key Speakers:

   Prof. Dame Lesley Regan (Women’s Health Ambassador England)

   Dr. Sue Mann (National Clinical Director for Women’s Health)

   Prof. Peter Brocklehurst (Emeritus Professor of Women’s Health, Director of Research and Development, Birmingham Clinical Trials Unit)

   Amin Rostami-Hochaghan (Professor of Systems Pharmacology and Director of Centre for Applied Pharmacokinetic Research at The University of Manchester)

   Dr. Jahnavi Daru (Expert Assessor for Women’s Health at the MHRA; Benefit Risk Evaluation II, Safety & Surveillance)
   

3. "The Human Equation vs. the Algorithm: Shaping a Future of Care in the Smart Hospital"

   Date/Time: December 10, 2024, 11:00 - 11:40

   Summary: This panel discusses the balance between human decision-making and algorithms in the context of smart hospitals.It explores how AI and advanced technologies can improve patient care and hospital efficiency while maintaining the essential human element in healthcare.

   
   Key Speakers:

   Prof. Shafi Ahmed (Consultant Colorectal Surgeon, Barts Health NHS Trust)

   Dr. Sarah Fothergill (HealthTech Lead, Barts Life Sciences, Barts Health NHS Trust)

   Dr. Susanne Gaube (Assistant Professor, UCL Global Business School for Health)

   Dr. Aqil Jaigirdar (Doctor, Worcestershire Acute Hospitals NHS Trust; Founder & Chairman, Maternal Aid Association)

Feedback

If you have specific feedback or anything interesting you’d like to share, please let us know by replying to this email.